Filing Details
- Accession Number:
- 0001209191-17-031435
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-11 10:29:18
- Reporting Period:
- 2017-05-11
- Filing Date:
- 2017-05-11
- Accepted Time:
- 2017-05-11 10:29:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1000694 | Novavax Inc | NVAX | Biological Products, (No Disgnostic Substances) (2836) | 222816046 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1342826 | C Stanley Erck | C/O Novavax, Inc. 20 Firstfield Road Gaithersburg MD 20878 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-05-11 | 50,000 | $0.84 | 128,279 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8266 to $0.8399, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.